Related Experiment Video

Updated: May 16, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies

Darren D O'Rielly1, Proton Rahman

  • 1Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.

Pharmacogenomics and Personalized Medicine
|December 11, 2012
PubMed

Insights

Genetic factors significantly influence rheumatoid arthritis (RA) susceptibility and treatment response. Understanding these genetic markers can personalize anti-rheumatic therapies for better efficacy and fewer adverse events.

Area of Science:

  • Immunogenetics
  • Rheumatology
  • Pharmacogenetics

Background:

  • Rheumatoid arthritis (RA) is a complex autoimmune disease characterized by joint inflammation.
  • Heritability estimates for RA range from 50% to 60%, with the human leukocyte antigen (HLA) locus being a major contributor.
  • Several non-HLA genetic loci, including PTPN22 and STAT4, are also associated with RA risk.

Purpose of the Study:

  • To review genetic factors involved in rheumatoid arthritis pathogenesis.
  • To explore the role of genetics in the pharmacotherapy of RA.
  • To identify potential pharmacogenetic markers for RA medications.

Main Methods:

  • Literature review of genetic associations with RA.
  • Analysis of genetic contributions to RA drug efficacy and adverse events.
  • Examination of pharmacogenetic markers for current and emerging RA treatments.

Main Results:

  • Genetic factors, including HLA and non-HLA loci, significantly contribute to RA susceptibility.
  • Inter-individual variability in RA drug response and adverse events is influenced by genetic factors.
  • Specific genetic markers are being investigated for their potential in guiding RA pharmacotherapy.

Conclusions:

  • Genetics plays a crucial role in both the development and treatment of rheumatoid arthritis.
  • Pharmacogenetics offers a promising avenue for personalized medicine in RA management.
  • Further research into genetic markers can optimize anti-rheumatic drug selection and improve patient outcomes.
Keywords:
pharmacogeneticsrheumatoid arthritissusceptibility genes

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...